Cancer Network interviews two prominent ovarian cancer researchers from both sides of the Atlantic on the role of PARP inhibitors and the challenges of developing ovarian cancer therapies.
Jonathan Ledermann, MD
Advertisement
Articles by Jonathan Ledermann, MD
Advertisement
Latest Updated Articles
PARP Inhibitors and the Challenges of Developing Ovarian Cancer TherapeuticsPublished: March 7th 2012 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type
2
How Can Oncology Staffing Shortages Be Remedied?
3
FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC
4
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
5
